MLN0264

DRUG4 trials

Sponsors

Millennium Pharmaceuticals, Inc.

Conditions

Adenocarcinoma of the StomachAdvanced Gastrointestinal CarcinomaAdvanced Gastrointestinal MalignanciesGastroesophageal Junction AdenocarcinomaGastroesophageal Junction Expressing Guanylyl Cyclase CMetastatic Gastric AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaPancreatic Adenocarcinoma

Phase 1

Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C

CompletedNCT01577758

Millennium Pharmaceuticals, Inc.Advanced Gastrointestinal Malignancies

Start: 2012-06-30End: 2014-02-28Updated: 2016-09-07

MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C

TerminatedNCT02391038

Millennium Pharmaceuticals, Inc.Advanced Gastrointestinal Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma +4

Start: 2014-12-31End: 2015-10-31Updated: 2017-03-29

Phase 2

A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction

TerminatedNCT02202759

Millennium Pharmaceuticals, Inc.Adenocarcinoma of the Stomach, Gastroesophageal Junction Expressing Guanylyl Cyclase C

Start: 2014-08-04End: 2016-01-15Updated: 2017-05-15

A Study of MLN0264 in Patients With Pancreatic Cancer

TerminatedNCT02202785

Millennium Pharmaceuticals, Inc.Pancreatic Adenocarcinoma

Start: 2014-07-02End: 2016-01-15Updated: 2017-05-15

Related Papers

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.

2017-05-1925 citations

Abstract CT107: Phase II trial of TAK-264 in previously treated patients (pts) with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expression guanylyl cyclase C (GCC)

Cancer Research2016-07-151 citations

Abstract CT117: A phase II trial of TAK-264, a novel antibody-drug conjugate (ADC), in patients with pancreatic adenocarcinoma expressing guanylyl cyclase C (GCC)

Cancer Research2016-07-151 citations

Abstract LB-185: A dual-isotope 3D cryo-imaging quantitative autoradiography (CIQA) method for simultaneous and quantitative assessment of both antibody and drug conjugate tumor distribution and kinetics

Cancer Research2016-07-15

MLN0264, an investigational antiguanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: Phase I study.

Journal of Clinical Oncology2014-05-209 citations